Cargando…

The anti-Alzheimer potential of novel spiroindolin-1,2-diazepine derivatives as targeted cholinesterase inhibitors with modified substituents

In this study, a new series of spiro indolin-1,2-diazepine were designed, synthesized, and screened for their cholinesterase inhibitory activities. A novel, green, high-yielding approach was constructed to synthesize spiro indolin-1,2-diazepine derivatives through a cascade reaction of different isa...

Descripción completa

Detalles Bibliográficos
Autores principales: Pourtaher, Hormoz, Hasaninejad, Alireza, Zare, Shahrokh, Tanideh, Nader, Iraji, Aida
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366214/
https://www.ncbi.nlm.nih.gov/pubmed/37488177
http://dx.doi.org/10.1038/s41598-023-38236-0
_version_ 1785077119743688704
author Pourtaher, Hormoz
Hasaninejad, Alireza
Zare, Shahrokh
Tanideh, Nader
Iraji, Aida
author_facet Pourtaher, Hormoz
Hasaninejad, Alireza
Zare, Shahrokh
Tanideh, Nader
Iraji, Aida
author_sort Pourtaher, Hormoz
collection PubMed
description In this study, a new series of spiro indolin-1,2-diazepine were designed, synthesized, and screened for their cholinesterase inhibitory activities. A novel, green, high-yielding approach was constructed to synthesize spiro indolin-1,2-diazepine derivatives through a cascade reaction of different isatins, malononitrile and 1,1-enediamines (EDAMs) via sequential four-component reactions to produce the target compounds with good to excellent yields. Next the inhibitory potencies of all derivatives were determined spectroscopically at 415 nm using the modified Ellman method. The results of the in vitro screening indicated that 5l with spiroindolin-1,2-diazepine core bearing 5-NO(2) at R(1) and 4-OH at R(2) was the most potent and selective AChE inhibitor with an IC(50) value of 3.98 ± 1.07 µM with no significant inhibition against BChE while 5j was the most active analog against both AChE and BChE enzymes. The structure–activity relationships suggested the variation in the inhibitory activities of derivatives was affected by different substitutions on the indolinone ring as well as the phenyl moiety. The enzyme kinetic studies of the most potent compound 5l at five different concentrations and acetylthiocholine substrate (0.1–1 mM) by Ellman's method revealed that it inhibited AChE in a mixed mode with a K(i) of 0.044 μM. A molecular docking study was performed via induced fit docking protocol to predict the putative binding interaction. It was shown that the moieties used in the initial structure design play a fundamental role in interacting with the enzyme's binding site. Further, molecular dynamics simulations with the Schrödinger package were performed for 5l in a complex with AChE and revealed that compound 5l formed the stable complex with the enzyme. The MTT toxicity assessments against the neuroblastoma cell line were executed, and no toxicity was seen for 5l under the tested concentrations.
format Online
Article
Text
id pubmed-10366214
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-103662142023-07-26 The anti-Alzheimer potential of novel spiroindolin-1,2-diazepine derivatives as targeted cholinesterase inhibitors with modified substituents Pourtaher, Hormoz Hasaninejad, Alireza Zare, Shahrokh Tanideh, Nader Iraji, Aida Sci Rep Article In this study, a new series of spiro indolin-1,2-diazepine were designed, synthesized, and screened for their cholinesterase inhibitory activities. A novel, green, high-yielding approach was constructed to synthesize spiro indolin-1,2-diazepine derivatives through a cascade reaction of different isatins, malononitrile and 1,1-enediamines (EDAMs) via sequential four-component reactions to produce the target compounds with good to excellent yields. Next the inhibitory potencies of all derivatives were determined spectroscopically at 415 nm using the modified Ellman method. The results of the in vitro screening indicated that 5l with spiroindolin-1,2-diazepine core bearing 5-NO(2) at R(1) and 4-OH at R(2) was the most potent and selective AChE inhibitor with an IC(50) value of 3.98 ± 1.07 µM with no significant inhibition against BChE while 5j was the most active analog against both AChE and BChE enzymes. The structure–activity relationships suggested the variation in the inhibitory activities of derivatives was affected by different substitutions on the indolinone ring as well as the phenyl moiety. The enzyme kinetic studies of the most potent compound 5l at five different concentrations and acetylthiocholine substrate (0.1–1 mM) by Ellman's method revealed that it inhibited AChE in a mixed mode with a K(i) of 0.044 μM. A molecular docking study was performed via induced fit docking protocol to predict the putative binding interaction. It was shown that the moieties used in the initial structure design play a fundamental role in interacting with the enzyme's binding site. Further, molecular dynamics simulations with the Schrödinger package were performed for 5l in a complex with AChE and revealed that compound 5l formed the stable complex with the enzyme. The MTT toxicity assessments against the neuroblastoma cell line were executed, and no toxicity was seen for 5l under the tested concentrations. Nature Publishing Group UK 2023-07-24 /pmc/articles/PMC10366214/ /pubmed/37488177 http://dx.doi.org/10.1038/s41598-023-38236-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Pourtaher, Hormoz
Hasaninejad, Alireza
Zare, Shahrokh
Tanideh, Nader
Iraji, Aida
The anti-Alzheimer potential of novel spiroindolin-1,2-diazepine derivatives as targeted cholinesterase inhibitors with modified substituents
title The anti-Alzheimer potential of novel spiroindolin-1,2-diazepine derivatives as targeted cholinesterase inhibitors with modified substituents
title_full The anti-Alzheimer potential of novel spiroindolin-1,2-diazepine derivatives as targeted cholinesterase inhibitors with modified substituents
title_fullStr The anti-Alzheimer potential of novel spiroindolin-1,2-diazepine derivatives as targeted cholinesterase inhibitors with modified substituents
title_full_unstemmed The anti-Alzheimer potential of novel spiroindolin-1,2-diazepine derivatives as targeted cholinesterase inhibitors with modified substituents
title_short The anti-Alzheimer potential of novel spiroindolin-1,2-diazepine derivatives as targeted cholinesterase inhibitors with modified substituents
title_sort anti-alzheimer potential of novel spiroindolin-1,2-diazepine derivatives as targeted cholinesterase inhibitors with modified substituents
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366214/
https://www.ncbi.nlm.nih.gov/pubmed/37488177
http://dx.doi.org/10.1038/s41598-023-38236-0
work_keys_str_mv AT pourtaherhormoz theantialzheimerpotentialofnovelspiroindolin12diazepinederivativesastargetedcholinesteraseinhibitorswithmodifiedsubstituents
AT hasaninejadalireza theantialzheimerpotentialofnovelspiroindolin12diazepinederivativesastargetedcholinesteraseinhibitorswithmodifiedsubstituents
AT zareshahrokh theantialzheimerpotentialofnovelspiroindolin12diazepinederivativesastargetedcholinesteraseinhibitorswithmodifiedsubstituents
AT tanidehnader theantialzheimerpotentialofnovelspiroindolin12diazepinederivativesastargetedcholinesteraseinhibitorswithmodifiedsubstituents
AT irajiaida theantialzheimerpotentialofnovelspiroindolin12diazepinederivativesastargetedcholinesteraseinhibitorswithmodifiedsubstituents
AT pourtaherhormoz antialzheimerpotentialofnovelspiroindolin12diazepinederivativesastargetedcholinesteraseinhibitorswithmodifiedsubstituents
AT hasaninejadalireza antialzheimerpotentialofnovelspiroindolin12diazepinederivativesastargetedcholinesteraseinhibitorswithmodifiedsubstituents
AT zareshahrokh antialzheimerpotentialofnovelspiroindolin12diazepinederivativesastargetedcholinesteraseinhibitorswithmodifiedsubstituents
AT tanidehnader antialzheimerpotentialofnovelspiroindolin12diazepinederivativesastargetedcholinesteraseinhibitorswithmodifiedsubstituents
AT irajiaida antialzheimerpotentialofnovelspiroindolin12diazepinederivativesastargetedcholinesteraseinhibitorswithmodifiedsubstituents